# Telavancin Pharmacokinetics in Cystic Fibrosis Patients

> **NCT03172793** · PHASE4 · COMPLETED · sponsor: **Joseph L. Kuti, PharmD** · enrollment: 18 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** Telavancin Injection

## Key facts

- **NCT ID:** NCT03172793
- **Lead sponsor:** Joseph L. Kuti, PharmD
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-08
- **Primary completion:** 2019-04-17
- **Final completion:** 2019-04-17
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2019-10-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03172793

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03172793, "Telavancin Pharmacokinetics in Cystic Fibrosis Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03172793. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*